In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals Shaping the Medical Industry (10/2008)

Executive Summary

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions Database, providing comprehensive transaction coverage from 1991 to the present.

You may also be interested in...



US FTC Pulling Various Levers To Impose Monetary Relief On False Ad Defendants

The Federal Trade Commission is leveraging other statutory authorities under the FTC Act and working with state regulators to garner monetary relief for consumers in the year since a Supreme Court decision shut down the commission’s longtime pathway for doing so under Sec. 13(b). FTC Bureau of Consumer Protection director Samuel Levine provided an update – and a warning to industry – at the NAD 2022 conference.

Lacutamab Data Boost Prospects For Innate Pharma

The French biotech has presented positive Phase II data on lacutamab in mycosis fungoides at the EORTC-CLTG meeting in Madrid which looks to have de-risked the asset.

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

IV003181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel